Topic summary

Prescription requirements and telehealth models

Sourcing › Regulatory FDA compounding research use only MHRA

This is a generated summary. It shows the 9 most-liked posts from a topic of 98, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

g.tammTL29 Nov 2025#7

Norrington, post #2: Narrowing the opening post, because the general version has more than one answer. Trying to state the prescription requirements and telehealth models position in a way that someone who disagrees would recognise as fair, because I do not think the version in this thread passes that test. Go to post

Prescription requirements and telehealth models is worth one more sentence than it usually gets, and the sentence is the one about how the number was arrived at.

28 likes in reply to #2 9mo

n.cabreraTL213 Nov 2025#12

An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence.

Not the answer, but possibly the question that gets there.

26 likes 8mo

i.almeidaTL223 Nov 2025#27

Worth separating two things that post #26 runs together.

Where a claim about legality is made here, the useful follow-up is which instrument it rests on. Most such claims turn out to rest on a forum post.

30 likes 8mo

c.vermeulenTL229 Nov 2025#37

An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence.

The variance between people here is larger than the effect being discussed.

32 likes 8mo

s.vanheckeTL27 Dec 2025#53

Prescription requirements and telehealth models is well covered in the tag pages, and the older discussions are better than the recent ones because they were argued out properly. Worth twenty minutes before adding to this one.

29 likes 8mo

r.chukwuTL212 Dec 2025#62

sleep_log, post #10: I think the prescription requirements and telehealth models question is answerable and has not been answered, which is a more optimistic position than most of this thread. Go to post

The failure mode on prescription requirements and telehealth models is boring rather than dramatic. It is almost always the step everyone assumes was done correctly because it is too simple to get wrong.

29 likes in reply to #10 8mo

h.karlsenTL215 Dec 2025#69

An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence.

30 likes 7mo

peak_purityTL3Analytical chemist18 Dec 2025#74

Coming back to post #70, because the follow-up matters more than the original answer.

Nothing in this subcategory is legal advice, and the members who work in regulated environments are the most careful to say so.

30 likes 7mo

c.bakkerTL226 Dec 2025#93

n.achebe, post #59: Building on post #56 rather than restating it. A methods point on prescription requirements and telehealth models rather than a substantive one: if the comparison is not like for like, the difference you are measuring is the difference in method. Go to post

Taking post #90 at face value and following it one step further.

Where a claim about legality is made here, the useful follow-up is which instrument it rests on. Most such claims turn out to rest on a forum post.

I have left out the parts I could not verify.

31 likes in reply to #59 7mo

Read the full topic (98 posts)

This topic was referenced in

What a regulator's shortage notice actually authorisesSourcing › Regulatory · 12 replies
Second pass at: Import rules for personal quantities, by jurisdiction, datedSourcing › Regulatory · 2 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
Follow-up: How compounding permissions changed when supply normalised Sourcing › Regulatory MHRA personal import research use only How compounding permissions changed when supply normalised I have a specific reason for asking rather than idle curiosity, and the context is below. I was wrong about compounding permissions in a thread last…	+72	77	1.5k	1d
Reading a regulatory notice rather than an article about it — what changed since Sourcing › Regulatory research use only MHRA FDA personal import Reading a regulatory notice rather than an article about it — what changed since — setting out what I have, and where I think it stops being reliable. Asking what a regulator's document actually says, since…	+28	32	640	13mo
Pharmaceutical compounding rules, summarised from primary sources — a second dataset Sourcing › Regulatory MHRA research use only compounding Posting this under the heading it deserves: Pharmaceutical compounding rules, summarised from primary sources — a second dataset Everything below is what sits behind that. Asking what a regulator's document…	+50	56	780	8mo
Enforcement priorities versus written rules Sourcing › Regulatory FDA personal import MHRA Enforcement priorities versus written rules — setting out what I have, and where I think it stops being reliable. Asking what a regulator's document actually says, since the summaries of it disagree. I have…		2	62k	15mo
Second pass at: Import rules for personal quantities, by jurisdiction, dated Sourcing › Regulatory research use only personal import FDA MHRA Second pass at: Import rules for personal quantities, by jurisdiction, dated Writing it up because I had to work it out twice and would rather nobody else did. Asking what a regulator's document actually…		2	5k	11mo

Related topics — sharing the tags FDA, compounding, research use only

Topic	Participants	Replies	Views	Activity
Import rules for personal quantities, by jurisdiction, dated Sourcing › Regulatory compounding MHRA FDA personal import On the subject in the title: Import rules for personal quantities, by jurisdiction, dated Working notes rather than a conclusion. I was wrong about import rules for personal quantities in a thread last spring…		3	60k	12mo
Coming back to: When "no data" is the complete and final answer Compounds › Other compounds research use only needs a source custom synthesis When "no data" is the complete and final answer I have a specific reason for asking rather than idle curiosity, and the context is below. Asking about the compound itself rather than about a trial of it. I…	+77	82	12k	11mo
Manufacturer assistance programmes and their eligibility rules Access › Pricing formulary data table compounding On the subject in the title: Manufacturer assistance programmes and their eligibility rules Working notes rather than a conclusion. I have spent a fortnight trying to pin manufacturer assistance programmes…	+37	42	32k	11d
Managing an unplanned gap in supply Access › Shortages shortage formulary FDA compounding Managing an unplanned gap in supply — setting out what I have, and where I think it stops being reliable. A narrow question about managing an unplanned gap, deliberately narrow, because the broad version has…	+105	110	5.1k	3mo
Cost per milligram, computed honestly across formats — the long version Access › Pricing cost per milligram compounding formulary data table Cost per milligram, computed honestly across formats — the long version Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because…	+111	124	24k	14mo